Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. is a clinical-stage medical diagnostics company developing the Symphony platform, a near-patient testing system that combines an analyzer with single-use protein detection cartridges. The company’s initial focus is an IL-6 test intended to help clinicians assess sepsis risk and patient acuity in critical care settings such as ICUs and emergency rooms. Bluejay does not yet have regulatory clearance for commercialization in the United States, so its business is still in the development and clinical-validation phase. Management’s stated goal is to build a recurring cartridge-based diagnostics business once FDA authorization is obtained, with additional biomarker tests potentially added over time.

4.88

— Bluejay Diagnostics, Inc.
	%
Diagnostic analyzer systems	20% The Symphony instrument platform used to run rapid whole-blood tests in critical care settings.
Single-use test cartridges	55% Disposable cartridges that perform protein detection and are intended to drive recurring revenue.
Sepsis and IL-6 testing	15% The initial clinical application focused on assessing sepsis-related mortality risk and patient acuity.
Future biomarker menu expansion	5% Additional tests for cardio-metabolic disease, cancer, and other rapid-testing indications.
Research-use-only systems	5% Devices being evaluated for non-clinical research use while regulatory clearance is pending.

Bluejay’s intended customers are hospitals and other critical care facilities that need rapid diagnostic information to...

U.S. hospitalsprimary
Buy or place Symphony analyzers and cartridges for use in critical care workflows once FDA clearance is obtained.
ICUs and emergency departmentsprimary
Use rapid IL-6 testing to support sepsis evaluation and treatment decisions where minutes matter.
Long-term acute care facilitiessecondary
Adopt the platform for ongoing monitoring of high-acuity patients if the test menu and reimbursement case develop.
Research-use-only customersemerging
Evaluate Symphony devices for non-diagnostic research applications while commercialization is pending.

Bluejay is headquartered in Acton, Massachusetts and is organized in the United States, but its commercial footprint is...

•Headquartered in Acton, Massachusetts, United States
•Initial commercialization target is the U.S. critical care market
•FDA clearance is required before U.S. sales can begin
•Cartridge manufacturing is being redeveloped with a contract manufacturer
•Toray license is global outside Japan, creating international IP exposure

Bluejay’s strategy is to secure FDA clearance for Symphony and then commercialize a cartridge-driven diagnostics...

FDA clearance and regulatory submissionshort-term

Commercialization depends on regulatory authorization, so clinical evidence and 510(k) readiness are the gating items for revenue generation.

Manufacturing redevelopment and quality controlshort-term

The Symphony cartridge supply chain must be reliable and compliant before the product can be submitted and scaled commercially.

Commercial model designmedium-term

Financing the analyzer and selling consumables is intended to lower adoption barriers and create recurring revenue.

Menu expansion beyond sepsislong-term

Additional tests could increase utilization per customer and broaden the addressable market.

Bluejay faces substantial execution risk because it has no current operating revenue and must still prove that Symphony...

critical

Imminent capital shortfall and going-concern uncertainty

The company has no revenue-generating operations and expects continued negative cash flow, so failure to raise additional capital could force liquidation or cessation of development.

Scope: Corporate liquidity and continuation of operations
Materiality: high

high

Regulatory approval delay or denial

Symphony cannot be marketed in the U.S. without FDA authorization, and the company’s commercialization timeline depends on successful clinical evidence and submission.

Scope: Product launch timing and revenue generation
Materiality: high

high

Manufacturing process failure or quality issues

Cartridge redevelopment is still underway, and technical or quality problems could prevent regulatory submission or reliable production.

Scope: Supply chain and product quality
Materiality: high

high

Dependence on licensed intellectual property and third parties

The Symphony cartridge platform relies on Toray’s licensed IP and external manufacturing partners, creating counterparty and concentration risk.

Scope: Technology access and production continuity
Materiality: medium

Going-concern assessment

Affects investor assessment of solvency, liquidity, and asset recoverability

Development-stage expense recognition

Creates large operating losses and cash burn with no offsetting sales

Equity and warrant financing accounting

Affects shareholders’ equity, cash balance, and per-share metrics

Emerging growth company accounting election

May affect timing of standard adoption and disclosure comparability

Bluejay Diagnostics, Inc.

Imminent capital shortfall and going-concern uncertainty

Regulatory approval delay or denial

Manufacturing process failure or quality issues

Dependence on licensed intellectual property and third parties

HeartBeam, Inc.

Aclaris Therapeutics, Inc.

BIOTRICITY INC.

Sigyn Therapeutics, Inc.

Cardio Diagnostics Holdings, Inc.

Decoy Therapeutics Inc.